The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence.
Solomon
Daniel H
DH
Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, and Harvard Medical School, Boston, Massachusetts 02115, USA. dhsolomon@partners.org
Lunt
Mark
M
Schneeweiss
Sebastian
S
D015340:Epidemiologic Research Design; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000276:immunology; D007239:Infections / Q000139:chemically induced* / Q000453:epidemiology; D017891:Pharmacoepidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha